<DOC>
	<DOCNO>NCT00529529</DOCNO>
	<brief_summary>This study design assess safety indacaterol ( 300 µg 600 µg ( 2 x 300 μg capsule ) daily [ od ] ) , compare salmeterol ( 50 μg twice day [ b.i.d . ] ) , 26 week , patient moderate severe persistent asthma .</brief_summary>
	<brief_title>Safety Indacaterol Patients ( ≥ 12 Years ) With Moderate Severe Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>1 . Male female patient age ≥ 12 year ( ≥ 18 year depend upon regulatory and/or Institutional Review Board/Independent Ethics Committee/Research Ethics Board [ IRB/IEC/REB ] approval ) sign informed consent form . 2 . Patients moderate severe persistent asthma , diagnose accord Global Initiative Asthma ( GINA ) guideline ( Updated 2006 ) additionally meet follow criterion : Patients use treatment bronchodilator , either regularly ondemand , use daily dose least 100 μg beclomethasone dipropionate ( equivalent ) least 1 month prior screen . Patients whose forced expiratory volume 1 second ( FEV1 ) ≥ 50 % predict normal value . Patients document ( previous 6 month ) demonstrate ( prior randomization ) ≥ 12 % least 200 ml increase FEV1 , inhale 200 μg salbutamol . 1 . Pregnant nursing ( lactate ) woman woman childbearing potential UNLESS meet prespecified definition postmenopausal use prespecified acceptable method contraception . 2 . Patients use tobacco product within 12 month period prior screening , smoke history great 10 pack year . 3 . Patients suffer chronic obstructive pulmonary disease ( COPD ) diagnose Global Initiative Chronic Obstructive Lung Disease ( GOLD ) guideline ( 2006 ) . 4 . Patients emergency room treatment acute asthma attack 6 week prior screen hospitalize acute asthma attack 6 month prior screen , time screen Week 1 . 5 . Patients diabetes Type I uncontrolled diabetes Type II include patient history blood glucose level consistently outside normal range glycosylated hemoglobin ( HbA1C ) &gt; 8.0 % measure screening . 6 . Patients , judgment investigator responsible Novartis personnel , clinically significant condition clinically relevant laboratory abnormality might compromise patient safety compliance , interfere evaluation , preclude completion study . 7 . Patients history long QT syndrome , whose QTc interval ( Bazett 's formula ) prolong &gt; 450 m ( male ) &gt; 470 m ( female ) . 8 . Certain medication asthma allied condition longacting bronchodilator must use prior screen prespecified minimum washout period . Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>asthma</keyword>
	<keyword>QAB149</keyword>
	<keyword>indacaterol</keyword>
</DOC>